Orchid Pharma Latest Updates

Merger and Amalgamation StatusThe company’s scheme of amalgamation with Dhanuka Laboratories Limited has reached a critical stage. On March 18, 2026, Orchid Pharma notified stock exchanges that the National Company Law Tribunal (NCLT) has officially reserved its order regarding the merger. A formal pronouncement is expected shortly, which will complete the structural integration of the two entities. Strategic Asset Acquisitions Orchid has transitioned from a royalty-earning partner to a sole proprietor by acquiring 100% global ownership of Enmetazobactam (a novel antibiotic) and the trademark Exblifep from Allecra Therapeutics. To support its international expansion, the company has also established Orchid Pharma Europe GmbH as a wholly-owned subsidiary in Germany. Project Updates: 7ACA & Cefiderocol7ACA Project: The facility is progressing toward mechanical completion, now targeted for September 2026. All fermenters have been erected, and the company is utilizing a ₹450 crore credit line (with ₹170 crore already drawn) to finalize the ***** The company is setting up a dedicated vial lyophilization facility at its Alathur site. The launch for this "first-in-class" antibiotic formulation is currently targeted for December 2026. Financial Performance (Q3 FY26)For the quarter ending December 31, 2025, Orchid reported a consolidated net loss of ₹12.61 crore, compared to a profit of ₹20.78 crore in the previous year. Revenue saw a 5% year-on-year decline to ₹207.27 crore. Management attributed this "transition year" weakness to prolonged pricing pressure in the global antibiotic market and a reduced mix of sales from regulated markets.